SYRE
Spyre Therapeutics, Inc.Company with tickers: SYRE
CIK
1636282
CUSIP
00773J202
Shares Outstanding
86,841,253
13F Activity (30d)
153 filings
151 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $45,641,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Research & Development | — | ||||
| Operating Income | $-45,641,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | $-69,005,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | — | ||||
| EPS (Diluted) | $-0.74 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |